Financial Summary (All financials)
| In millions, except per share items | Oct-31-20 | Oct-31-19 | Oct-31-18 | Oct-31-17 | Oct-31-16 | Oct-31-15 | Oct-31-14 | Oct-31-13 |
| Revenues | 7,503.0 | 11,251.0 | 10,250.0 | 8,570.0 | 8,111.0 | 10,140.0 | 10,806.0 | 10,775.0 |
| Revenue growth | -33.3% | 9.8% | 19.6% | 5.7% | -20.0% | -6.2% | 0.3% | -15.1% |
| Cost of goods sold | 6,221.0 | 9,245.0 | 8,317.0 | 7,037.0 | 6,812.0 | 8,670.0 | 9,534.0 | 9,761.0 |
| Gross profit | 1,282.0 | 2,006.0 | 1,933.0 | 1,533.0 | 1,299.0 | 1,470.0 | 1,272.0 | 1,014.0 |
| Gross margin | 17.1% | 17.8% | 18.9% | 17.9% | 16.0% | 14.5% | 11.8% | 9.4% |
| Selling, general and administrative | 1,021.0 | 934.0 | 828.0 | 751.0 | 802.0 | 908.0 | 979.0 | 1,215.0 |
| Research and development | 321.0 | 319.0 | 297.0 | 251.0 | 247.0 | 288.0 | 331.0 | 406.0 |
| EBITA | -83.0 | 605.0 | 790.0 | 471.0 | 356.0 | 355.0 | -51.0 | -579.0 |
| EBITA margin | -1.1% | 5.4% | 7.7% | 5.5% | 4.4% | 3.5% | -0.5% | -5.4% |
| Amortization of intangibles | 2.0 | 3.0 | 7.0 | 12.0 | 12.0 | 10.0 | 18.0 | 22.0 |
| EBIT | -85.0 | 602.0 | 783.0 | 459.0 | 344.0 | 345.0 | -69.0 | -601.0 |
| EBIT margin | -1.1% | 5.4% | 7.6% | 5.4% | 4.2% | 3.4% | -0.6% | -5.6% |
| Pre-tax income | -388.0 | 262.0 | 420.0 | 64.0 | -32.0 | -103.0 | -556.0 | -974.0 |
| Income taxes | -59.0 | 19.0 | 52.0 | 10.0 | 33.0 | 51.0 | 26.0 | -171.0 |
| Tax rate | 15.2% | 7.3% | 12.4% | 15.6% | | | | 17.6% |
| Earnings from continuing ops | -329.0 | 221.0 | 340.0 | 29.0 | -97.0 | -341.0 | -1,204.0 | -857.0 |
| Earnings from discontinued ops | | | | 1.0 | | 3.0 | 3.0 | -41.0 |
| Net income | -329.0 | 221.0 | 340.0 | 30.0 | -97.0 | -338.0 | -1,201.0 | -898.0 |
| Net margin | -4.4% | 2.0% | 3.3% | 0.4% | -1.2% | -3.3% | -11.1% | -8.3% |
| |
| Diluted EPS | ($3.30) | $2.22 | $3.41 | $0.31 | ($1.19) | ($4.18) | ($14.79) | ($10.66) |
| Shares outstanding (diluted) | 99.7 | 99.5 | 99.6 | 93.5 | 81.7 | 81.6 | 81.4 | 80.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|